Real-world eligibility for FSGS clinical trials: insights from a US health system
Clinical Kidney Journal · 02.02.2026 · 19 (2)
DOI: 10.1093/ckj/sfaf377 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Kidney Journal, online erschienen am 03.12.2025. Verfasst von Mercedes A Munis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dimerix Bioscience Pty Ltd.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
- Dimerix Bioscience Pty Ltd, Melbourne, VIC, Australia.
- Division of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA.
- Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
ORCID-Profile: John J Sim
Förderung
- Dimerix Bioscience Pty Ltd
Zitieren
APA
Munis, M. A., Chen, Q., Smith, A., Garcia, C. L., Fuller, D., & Sim, J. J. (2026). Real-world eligibility for FSGS clinical trials: insights from a US health system. Clinical Kidney Journal, 19(2). https://doi.org/10.1093/ckj/sfaf377
Vancouver
Munis MA, Chen Q, Smith A, Garcia CL, Fuller D, Sim JJ. Real-world eligibility for FSGS clinical trials: insights from a US health system. Clinical Kidney Journal. 2026;19(2). doi:10.1093/ckj/sfaf377
BibTeX
@article{Munis2026,
author = {Munis, Mercedes A and Chen, Qiaoling and Smith, Alisha and Garcia, Candelaria L and Fuller, David and Sim, John J},
title = {Real-world eligibility for FSGS clinical trials: insights from a US health system},
journal = {Clinical Kidney Journal},
year = {2026},
volume = {19},
number = {2},
doi = {10.1093/ckj/sfaf377}
}
EUVIMED